Rigakembaio to Receive Follow-up Milestone from Ono Pharmaceutical for ADC Joint Research

"Verifying the Pace of Pipeline Development Based on the ConjuAll(TM) Platform"

Rigakembaio announced on the 27th that it is scheduled to receive a follow-up development milestone under its antibody-drug conjugate (ADC) joint research agreement with Ono Pharmaceutical of Japan. The size of the milestone payment and detailed terms have not been disclosed in accordance with the contract.

Rigakembaio company logo image. Rigakembaio

This milestone is an additional achievement derived about one and a half months after the company received the previous one in January. The two companies had signed a joint research and candidate discovery agreement in October 2024, utilizing Rigakembaio's ADC platform, ConjuAll.

The designation of the first target was completed in March 2025. The company explained that the joint research is proceeding as planned, as it successively achieved stepwise development goals in January and February this year.

A Rigakembaio official stated, "Based on our collaboration with Ono Pharmaceutical, we are sequentially delivering the planned research and development outcomes." The official added that the company will seek to generate additional achievements from pipelines based on the ConjuAll platform.

This content was produced with the assistance of AI translation services.